Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30164097 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3KDM4EALDH1A1 | |
| SCHEMBL29232456 | 0.91 | BIRC5 (0.37) | SLC6A2SLC6A4SLC6A3ALDH1A1GAA | |
| SCHEMBL24985047 | 0.88 | ALDH1A1 (0.33) | SLC6A2SLC6A4SLC6A3KDM4EALDH1A1 | |
| SCHEMBL10893513 | 0.80 | ESR2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10893518 | 0.80 | ESR2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24986844 | 0.80 | KDM4E (0.35) | SLC6A2SLC6A4SLC6A3KDM4EALDH1A1 | |
| SCHEMBL30164168 | 0.80 | KDM4E (0.35) | SLC6A2SLC6A4SLC6A3KDM4EALDH1A1 | |
| SCHEMBL24985174 | 0.76 | ALDH1A1 (0.33) | SLC6A2SLC6A4SLC6A3KDM4EALDH1A1 | |
| SCHEMBL10896400 | 0.76 | GRM2 (0.33) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL10895339 | 0.76 | ESR2 (0.36) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | SLC6A2 146/4885SLC6A4 168/4885SLC6A3 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.